Expert Opinion on Therapeutic Targets

Papers
(The TQCC of Expert Opinion on Therapeutic Targets is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Targeting transcription in neuroblastoma: focus on the core regulatory circuit127
Decoding the expression pattern of MUC3A in gastric adenocarcinoma: unveiling the key to successful immunotherapy60
IL-36: a therapeutic target for ulcerative colitis?58
The clinical and immunological features of alopecia areata following SARS-CoV-2 infection or COVID-19 vaccines48
Potential role of indole-3-propionic acid in tuberculosis: current perspectives and future prospects45
Calcium channelopathies in neurodegenerative disorder: an untold story of RyR and SERCA42
Interleukin-18 in cancer immunology and immunotherapy41
Mitochondrial permeability transition pore: a snapshot of a therapeutic target37
CDK7 as a New therapeutic target in pancreatic and lung cancer: current evidence and future perspectives37
Glycoproteins and longevity: an interview with Professor Gordan Lauc36
Molecular basis for targeting TBK1 in CAR-T cell therapies for cancer35
Pleural mesothelioma: a snapshot of emerging drug targets and opportunities for non-surgical therapeutic advancement34
Novel regulators of airway epithelial barrier function during inflammation: potential targets for drug repurposing34
The sigma–1 receptor: a mechanistically–informed therapeutic target for antidepressants33
The membrane receptor CD44: roles in neurodegenerative diseases32
MDA-9/Syntenin as a therapeutic cancer metastasis target: current molecular and preclinical understanding32
The potential of multimolecular G-quadruplex structures for targeted treatment of Amyotrophic Lateral Sclerosis29
Kallikrein-related peptidases: mechanistic understanding for potential therapeutic targeting in cancer27
Current challenges in the discovery of treatments against Mayaro fever26
Identification of target sites in the VHR (DUSP3) enzyme unlocking potential avenues for future sepsis treatment24
Lipid-laden foam cells in the pathology of atherosclerosis: shedding light on new therapeutic targets24
The collagenases: are they tractable targets for preventing cartilage destruction in osteoarthritis?23
Antagonistic pleiotropy: the example of cardiac insulin-like growth factor signaling, which is essential in youth but detrimental in age22
The challenges and potential of microRNA-based therapy for patients with liver failure syndromes and hepatocellular carcinoma22
Novel signatures of prostate cancer progression and therapeutic resistance22
Ramatroban for chemoprophylaxis and treatment of COVID-19: David takes on Goliath21
Bruton’s tyrosine kinase as a promising therapeutic target for multiple sclerosis21
Therapeutic targeting of the polyglutamine androgen receptor in Spinal and Bulbar Muscular Atrophy20
KRAS mutations in colorectal cancer: impacts on tumor microenvironment and therapeutic implications20
Antibacterial carbonic anhydrase inhibitors targeting Vibrio cholerae enzymes20
Esophageal cancer: emerging therapeutics19
Promising therapeutic targets for the treatment of urine storage dysfunction: what’s the status?19
RBM47 as a therapeutic target in selected human diseases19
The role of adipokines in the pathogenesis of psoriasis – a focus on resistin, omentin-1 and vaspin19
The trap becomes the target: molecular basis for targeted inhibition of neutrophil extracellular traps in the pre-metastatic niche19
Molecular pharmacology of multitarget cyclin-dependent kinase inhibitors in human colorectal carcinoma cells19
Targeting PRL phosphatases in hematological malignancies19
Progeria: a perspective on potential drug targets and treatment strategies19
What do we know about the renin angiotensin system and inflammatory bowel disease?18
The sweet side of wound healing: galectins as promising therapeutic targets in hemostasis, inflammation, proliferation, and maturation/remodeling18
Targeting acid-sensing ion channels in glioblastoma: is there any therapeutic potential?17
Sjögren’s syndrome: shedding light on emerging and key drug targets17
Dapagliflozin modulates neuronal injury via instigation of LKB1/p-AMPK/GABAB R2 signaling pathway and suppression of the inflammatory cascade in an essential tremor rat model17
Tenosynovial giant cell tumors (TGCT): molecular biology, drug targets and non-surgical pharmacological approaches17
Emerging therapeutic targets for anorexia nervosa17
Macrophages-microenvironment crosstalk in fibrostenotic inflammatory bowel disease: from basic mechanisms to clinical applications16
Targeting dorsal root ganglia and primary sensory neurons for the treatment of chronic pain: an update16
Atypical teratoid rhabdoid tumor (ATRT): disease mechanisms and potential drug targets16
Improving mitochondrial function in preclinical models of heart failure: therapeutic targets for future clinical therapies?16
Myocarditis: causes, mechanisms, and evolving therapies16
ULK1 as a therapeutic target in kidney diseases: Current perspective16
Kidney and lipids: novel potential therapeutic targets for dyslipidemia in kidney disease?16
Granzyme B as a therapeutic target: an update in 202216
GDF15: a potential therapeutic target for type 1 diabetes16
Scavenger receptor A in immunity and autoimmune diseases: Compelling evidence for targeted therapy15
Myricetin, a natural inhibitor of CD147, increases sensitivity of cisplatin in ovarian cancer15
Mitochondria makeover: unlocking the path to healthy longevity15
XPO-1 targeting in chronic lymphocytic leukemia: is there potential for therapeutic strategy?14
The contribution of fibronectin in epileptogenesis: therapeutic potential and mechanistic complexity14
What is the potential of formyl peptide receptor 1 (FPR1) as a therapeutic target in human disease?14
Looking ahead to targeting macrophages by CAR T- or NK-cells in blood cancers14
Heterogeneity of triple-negative breast cancer: understanding the Daedalian labyrinth and how it could reveal new drug targets13
Targeting BMPR-II in pulmonary arterial hypertension: a case of Hercules versus the Hydra?13
Rare tumors, real targets: patient-derived models for the discovery and validation of precision therapies13
The role of collagen triple helix repeat containing 1 (CTHRC1) in cancer development and progression13
Metabolic hallmarks of trastuzumab resistance13
Emerging drug targets for sickle cell disease: shedding light on new knowledge and advances at the molecular level13
Targeting PCSK9 beyond the liver: evidence from experimental and clinical studies13
Leveraging AI to identify dual-purpose aging and disease targets13
Expression of Concern: Overexpression of HMGA2 in breast cancer promotes cell proliferation, migration, invasion and stemness13
Shedding light on emerging therapeutic targets for chordoma12
Bench-to-bedside investigations of H3 K27-altered diffuse midline glioma: drug targets and potential pharmacotherapies12
Unveiling the role of mineralocorticoid receptor antagonists in epilepsy: the intersection of seizures, stress, and neuroinflammation12
Exosomes as a drug delivery tool for cancer therapy: a new era for existing drugs and oncolytic viruses12
Cellular role of CD93 and its potential as a future therapeutic target12
The anti-inflammatory and vasoprotective properties of mPGES-1 inhibition offer promising therapeutic potential12
Nitric oxide pathway as a plausible therapeutic target in autism spectrum disorders12
Emerging therapeutic targets for epilepsy: preclinical insights11
An appraisal of emerging therapeutic targets for multiple sclerosis derived from current preclinical models11
FAM171A2 in Parkinson’s disease: mechanistic insights for a future therapeutic target11
New therapeutic targets for endometrial cancer: a glimpse into the preclinical sphere11
TAR DNA-binding protein of 43 kDa (TDP-43) and amyotrophic lateral sclerosis (ALS): a promising therapeutic target11
Virus-induced senescence: A therapeutic target to mitigate severe progression of SARS-COV-211
ORF6, a repressor of the MHC class I pathway: new molecular target for SARS-CoV-2 drug discovery?11
The prognostic and therapeutic potentials of CTLA-4 in hematological malignancies11
Combining inhibition of immune checkpoints and PARP: rationale and perspectives in cancer treatment11
The neuroinflammatory astrocytic P2X7 receptor: Alzheimer’s disease, ischemic brain injury, and epileptic state11
Considerations on the implementation of MAP4K4 inhibitors as cancer treatment11
0.082854986190796